ArticlePloS one2018
Epidemiological and economic burden of potentially HPV-related cancers in France.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05566106 (Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
Who cites it
13 citing papers in PubMed.
- Estimated HPV-Attributable Inpatient Pharmaceutical Reimbursement in Bulgaria, 2021-2025: A National Payer-Perspective Expenditure Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Interplay of miR-542, miR-126, miR-143 and miR-26b with PI3K-Akt is a Diagnostic Signal and Putative Regulatory Target in HPV-Positive Cervical Cancer.Biochemical genetics · 2025Article
- The growing impact of human papilloma virus (HPV)-associated cancers in men in Costa Rica: epidemiological and economic burden.Frontiers in public health · 2025Article
- Cost Analysis Related to Diagnosis, Treatment and Management of Cervical Cancer in Antigua and Barbuda: A Prevalence-Based Cost-of-Illness Study.International journal of environmental research and public health · 2024Article
- Screening for precancerous anal lesions linked to human papillomaviruses: French recommendations for clinical practice.Techniques in coloproctology · 2024Review
- Cause of Death in Patients with Oropharyngeal Carcinoma by Human Papillomavirus Status: Comparative Data Analysis.JMIR public health and surveillance · 2023Article
- Vaccine hesitancy about the HPV vaccine among French young women and their parents: a telephone survey.BMC public health · 2023Article
- Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.Applied health economics and health policy · 2021Article
- Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea.BMC public health · 2020Article
- The costs of treating vaginal and vulval cancer in England (2009-2015).BMC public health · 2020Article
- Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections.Metabolites · 2020Article
- Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France.PloS one · 2020Article
- Investigation of human papillomavirus prevalence in married women and molecular characterization and phylogenetic analysis of the virus.Obstetrics & gynecology science · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomaviruses (HPV) infection is now known to be responsible for almost all cervical cancers, and for a substantial fraction of Head and Neck cancers (HNCs). However, comprehensive epidemiological and economic data is lacking in France, especially for rarer potentially HPV-related cancers, which include anal, vulvar and vaginal cancers. Using the national comprehensive database of French public and private hospital information (PMSI), we assessed prevalence and incidence of patients with in-hospital diagnosis for potentially HPV-related cancers in 2013, and estimated costs related to their management over a 3-year period after diagnosis in France. Concerning female genital cancers, 7,597, 1,491 and 748 women were hospitalized for cervical, vulvar and vaginal cancer in 2013, respectively, with 3,120, 522 and 323 of them being new cases. A total of 4,153 patients were hospitalized for anal cancer in 2013, including 1,661 new cases. For HNCs, 8,794 and 14,730 patients were hospitalized for oral and oropharyngeal cancer in 2013, respectively; 3,619 and 6,808 were new cases. Within the 3 years after cancer diagnosis, the average cost of hospital care per patient varied from €28 K for anal cancer to €41 K for oral cancer. Most expenditures were related to hospital care, before outpatient care and disability allowance; they were concentrated in the first year of care. The total economic burden associated with HPV-potentially related cancers was about €511 M for the French National Health Insurance over a 3 years period (2011 to 2013), ranging from €8 M for vaginal cancer to €222 M for oropharyngeal cancer. This study reported the most up-to-date epidemiological and economic data on potentially HPV-related cancers in France. These results may be used to evaluate the potential impact of new preventive strategies, namely the generalized organized screening of cervical cancer and the nine-valent HPV vaccine, indicated in the prevention of cervical, vaginal, vulvar and anal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.